Idiopathic Pulmonary Fibrosis (IPF) clinical trials in Tennessee
10 active Idiopathic Pulmonary Fibrosis (IPF) trials with a site in Tennessee. Describe your situation to see which ones look like a fit.
- A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
- WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- Mechanisms of Familial Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.